Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Ellis

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
CJC Open|December 13, 2021
Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysisMuhammad Mustafa Alhussein, Abir Mokbel, Tammy Cosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancerSimon J Crabb, Demetris Patsios, Eric Sauerbrei, et al.
JAMA Oncology|July 29, 2021
Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical TrialTheodoros Tsakiridis, Gregory R Pond, Jim Wright, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2011
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancerPeter M Ellis, Normand Blais, Dennis Soulieres, et al.
Current Oncology (Toronto, Ont.)|October 25, 2024
Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario PerspectiveDaniel Breadner, David M Hwang, Don Husereau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials groupScott A Laurie, Isabelle Gauthier, Andrew Arnold, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario ForumParneet K Cheema, Paul F Wheatley-Price, Matthew J Cecchini, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 11, 2016
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsAlona Zer, Keyue Ding, Siow Ming Lee, et al.
Clinical Lung Cancer|March 26, 2017
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage DiseaseMark A Socinski, Frederic J Kaye, David R Spigel, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung CancerBarbara L Melosky, Natasha B Leighl, David Dawe, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
CJC Open|December 13, 2021
Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysisMuhammad Mustafa Alhussein, Abir Mokbel, Tammy Cosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancerSimon J Crabb, Demetris Patsios, Eric Sauerbrei, et al.
JAMA Oncology|July 29, 2021
Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical TrialTheodoros Tsakiridis, Gregory R Pond, Jim Wright, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2011
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancerPeter M Ellis, Normand Blais, Dennis Soulieres, et al.
Current Oncology (Toronto, Ont.)|October 25, 2024
Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario PerspectiveDaniel Breadner, David M Hwang, Don Husereau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials groupScott A Laurie, Isabelle Gauthier, Andrew Arnold, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario ForumParneet K Cheema, Paul F Wheatley-Price, Matthew J Cecchini, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 11, 2016
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsAlona Zer, Keyue Ding, Siow Ming Lee, et al.
Clinical Lung Cancer|March 26, 2017
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage DiseaseMark A Socinski, Frederic J Kaye, David R Spigel, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung CancerBarbara L Melosky, Natasha B Leighl, David Dawe, et al.
Pageof 10